Evercore ISI Group Initiates Coverage of Bio-Techne (TECH) with Outperform Recommendation
Fintel reports that on March 18, 2025, Evercore ISI Group initiated coverage of Bio-Techne (NasdaqGS:TECH) with a Outperform recommendation.
Analyst Price Forecast Suggests 39.85% Upside
As of March 4, 2025, the average one-year price target for Bio-Techne is $87.52/share. The forecasts range from a low of $68.68 to a high of $99.75. The average price target represents an increase of 39.85% from its latest reported closing price of $62.58 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Bio-Techne is 1,534MM, an increase of 28.26%. The projected annual non-GAAP EPS is 2.83.
What is the Fund Sentiment?
There are 1,229 funds or institutions reporting positions in Bio-Techne. This is an decrease of 18 owner(s) or 1.44% in the last quarter. Average portfolio weight of all funds dedicated to TECH is 0.29%, an increase of 6.01%. Total shares owned by institutions increased in the last three months by 1.20% to 196,826K shares. 
The put/call ratio of TECH is 0.41, indicating a bullish outlook.
What are Other Shareholders Doing?
Price T Rowe Associates holds 10,654K shares representing 6.74% ownership of the company. In its prior filing, the firm reported owning 9,424K shares , representing an increase of 11.54%. The firm increased its portfolio allocation in TECH by 2.01% over the last quarter.
PRNHX - T. Rowe Price New Horizons Fund holds 6,615K shares representing 4.18% ownership of the company. In its prior filing, the firm reported owning 5,834K shares , representing an increase of 11.80%. The firm increased its portfolio allocation in TECH by 9.73% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 4,973K shares representing 3.15% ownership of the company. In its prior filing, the firm reported owning 5,054K shares , representing a decrease of 1.63%. The firm decreased its portfolio allocation in TECH by 12.62% over the last quarter.
Ameriprise Financial holds 4,703K shares representing 2.97% ownership of the company. In its prior filing, the firm reported owning 4,386K shares , representing an increase of 6.75%. The firm decreased its portfolio allocation in TECH by 3.49% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 4,301K shares representing 2.72% ownership of the company. In its prior filing, the firm reported owning 4,127K shares , representing an increase of 4.05%. The firm decreased its portfolio allocation in TECH by 11.15% over the last quarter.
Bio-Techne Background Information
(This description is provided by the company.)
Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.